|
" Understanding the Use of Composite Endpoints in Clinical Trials "
McCoy, C. Eric
| Document Type
|
:
|
AL
|
| Record Number
|
:
|
932944
|
| Doc. No
|
:
|
LA4693j9pv
|
| Language of Document
|
:
|
English
|
| Main Entry
|
:
|
McCoy, C. Eric
|
| Title & Author
|
:
|
Understanding the Use of Composite Endpoints in Clinical Trials [Article]\ McCoy, C. Eric
|
| Title of Periodical
|
:
|
Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health
|
| Volume/ Issue Number
|
:
|
19/4
|
| Date
|
:
|
2018
|
| Abstract
|
:
|
Clinicians, institutions, healthcare networks, and policymakers use outcomes reported in clinical trials as the basis for medical decision-making when managing individual patients or populations. Therefore, the choice of a valid primary endpoint is crucial for randomized controlled trials (RCT) to demonstrate efficacy of new therapies. Recent improvements in treatment, however, have led to a decline in the morbidity and mortality of several common diseases, resulting in a reduction in relevant outcomes that can be used as clinical trial endpoints. Composite endpoints have been used as a solution to maintain the feasibility of RCTs, particularly when facing low event rates, high cost, and long follow-up. However, the benefits of using composite endpoints must be weighed against the risks of misinterpretation by clinicians and policymakers, as incorrect interpretation may have a detrimental effect on patients and populations. This paper defines a composite endpoint, discusses the rationale for its use, and provides a practical approach to interpreting results to aid in medical decision-making.
|
| |